Christopher Vanhorssen, APRN
Family · Helena, MTNPI 1417443086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 26.4% of the total. 2025 is the largest year on record at $1,050, 4.7 times the $224 reported in 2021. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$869
- AbbVie$445
- Novo Nordisk$386
- Lilly USA, LLC$293
- Pfizer$283
- GSK$242
- plus $779 from 15 others
What the payments were for
- Food & beverage$3,20197%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $869 |
| AbbVie | 26 | $445 |
| Novo Nordisk | 22 | $386 |
| Lilly USA, LLC | 18 | $293 |
| Pfizer | 14 | $283 |
| GSK | 10 | $242 |
| Exact Sciences | 5 | $101 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Amgen | 3 | $84 |
| Astellas Pharma US Inc | 3 | $70 |
| Bayer | 4 | $70 |
| Genentech USA, Inc. | 5 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Corcept Therapeutics | 3 | $57 |
| Sanofi Pasteur Inc. | 2 | $50 |
| Novartis | 3 | $47 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$3,296 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $47,013 |
| FarxigaDapagliflozin Propanediol | 21 | $24,925 |
| MounjaroTirzepatide | 15 | $21,753 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,927 |
| OzempicSemaglutide | 11 | $9,818 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,783 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,760 |
| Bupropion XlBupropion Hcl | 32 | $3,224 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $3,009 |
| Celecoxib | 26 | $2,936 |
| Levothyroxine Sodium | 213 | $1,899 |
| Oxycodone Hcl | 52 | $1,507 |
| Baclofen | 13 | $1,408 |
| Losartan Potassium | 131 | $1,357 |
| Omeprazole | 223 | $1,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $283 | $47,01330 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $869 | $31,68532 claims |
| Lilly USA, LLCMounjaro | $293 | $21,75315 claims |
| Novo NordiskOzempic | $386 | $9,81811 claims |
| GSKBreo Ellipta | $242 | $7,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.
Other family in Helena
- Kara AddisonHelena$50K
- Jessica HavensHelena$11K
- Tara WellsHelena$10K
- Mary MiddaghHelena$6K
- Megan GittingsHelena$4K
- Jeannie FahlquistHelena$3K
- Willow SheehanHelena$3K
- Leigha ShilhanekHelena$3K
- Lindsay McCarthyHelena$2K
- Julie FleschHelena$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.